

## Appendix 4D

### Financial statements for the half-year ended 31 December 2025

as required by ASX listing rule 4.2A

#### 1. Company details

Name of entity:	Clarity Pharmaceuticals Ltd
ABN:	36 143 005 341
Reporting period:	Half Year ended 31 December 2025
Previous period:	Half Year ended 31 December 2024

#### 2. Results for announcement to the market

				\$'000
Revenue from ordinary activities	up	0%	to	0
Loss from ordinary activities after tax attributable to the owners of Clarity Pharmaceuticals Ltd	up	135%	to	(55,533)
Loss for the year attributable to the owners of Clarity Pharmaceuticals Ltd	up	136%	to	(55,632)

#### *Dividends*

There were no dividends paid, recommended, or declared during the current financial period.

#### *Comments*

The loss for the consolidated entity after providing for income tax amounted to \$55,631,994.

Additional information supporting the Appendix 4D disclosure requirements can be found in the Directors' Report and the consolidated financial statements for the half-year ended 31 December 2024.

#### 3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	62.6	39.7

#### 4. Control gained over entities

Not applicable.

## Appendix 4D

### Financial statements for the half-year ended 31 December 2025

as required by ASX listing rule 4.2A

---

#### 5. Loss of control over entities

On 31 December 2025, Clarity Pharmaceuticals Europe SA (CPEU) was wound up resulting in loss of control.

---

#### 6. Details of associates and joint venture entities

Not applicable.

---

#### 7. Audit qualification or review

*Details of audit/review dispute or qualification (if any):*

This report is based on the consolidated financial statements for the half-year ended 31 December 2025 which have been reviewed by Grant Thornton who have issued an unmodified opinion.

---

#### 8. Attachments

*Details of attachments (if any):*

The Half Year Financial Statements of Clarity Pharmaceuticals Ltd for the period ended 31 December 2025 are attached.

---

#### 9. Signed

As authorised by the Board of Directors



Robert Vickery  
Company Secretary  
26 February 2026